$aztr
AZTR sees massive engagement surge driven by positive Phase 1b trial data and CEO's strong track record. Social buzz is high as investors anticipate upcoming milestones and potential Bayer partnership.
About $aztr
$AZTR is a decentralized digital asset and its associated ecosystem.
Engagements: [-----] (24h)
Engagements 24-Hour Time-Series Raw Data
Current Value: [-----]
Daily Average: [-----]
[--] Month: [-------] +139%
[--] Months: [---------] +131%
[--] Year: [---------] -2.20%
1-Year High: [-------] on 2025-08-27
1-Year Low: [--] on 2026-01-01
Engagements by network (24h): X: [-----] Reddit: [--]
Mentions: [--] (24h)
Mentions 24-Hour Time-Series Raw Data
Current Value: [--]
Daily Average: [--]
1-Year High: [---] on 2025-11-13
1-Year Low: [--] on 2025-12-21
Mentions by network (24h): X: [--] Reddit: [--]
Creators: [--] (24h)
Creators 24-Hour Time-Series Raw Data
[--] unique social accounts have posts mentioning $aztr in the last [--] hours which is down 17% from [--] in the previous [--] hours
Daily Average: [--]
1-Year High: [---] on 2025-06-28
1-Year Low: [--] on 2025-12-21
The most influential creators that mention $aztr in the last [--] hours
| Creator | Rank | Followers | Posts | Engagements |
|---|---|---|---|---|
| @greatstockpicks | [--] | [------] | [--] | [-----] |
| @boogeymantradez | [--] | [-----] | [--] | [-----] |
| @WolfofWallSt461 | [--] | [-----] | [--] | [---] |
| @LucyTrader98 | [--] | [---] | [--] | [--] |
| @buysellshort | [--] | [-------] | [--] | [--] |
| @simpletrader36 | [--] | [-----] | [--] | [--] |
| @stockplaymaker1 | [--] | [-------] | [--] | [--] |
| @daaapollo908 | [--] | [---] | [--] | [--] |
| @RaZE___SoViEt | [--] | [---] | [--] | [--] |
| @MapagoTrades | [--] | [---] | [--] | [--] |
Sentiment: 86%
Sentiment 24-Hour Time-Series Raw Data
Current Value: 86%
Daily Average: 84%
[--] Month: 69% +19%
[--] Months: 69% -31%
[--] Year: 69% -17%
1-Year High: 100% on 2025-02-16
1-Year Low: 9% on 2025-12-03
Most Supportive Themes:
- Positive Clinical Trial Data: (67%) Posts highlight excellent safety and strong efficacy signals from Phase 1b trials, particularly for Netherton syndrome.
- CEO's Past Success: (33%) The CEO's previous company exit for $6.3 billion is frequently mentioned as a positive indicator for $AZTR's potential.
Most Critical Themes:
Limited data mode. Full metrics available with subscription: lunarcrush.com/pricing